Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0343)
| Name |
DO264
|
||||
|---|---|---|---|---|---|
| Synonyms |
DO-264; 2301866-59-9; DO264; 1-[1-[3-chloro-4-[2-chloro-4-(trifluoromethoxy)phenoxy]pyridin-2-yl]piperidin-4-yl]-3-pyridin-3-ylthiourea; CHEMBL4444498; 1-(1-(3-Chloro-4-(2-chloro-4-(trifluoromethoxy)phenoxy)pyridin-2-yl)piperidin-4-yl)-3-(pyridin-3-yl)thiourea; SCHEMBL23111592; GTPL10250; PIEQDBPBBQPLPL-UHFFFAOYSA-N; DO-26; BCP31625; BSD86659; EX-A3811; BDBM50526084; DO 264; DO264;DO 264; AKOS037648996; BS-16210; HY-114157; CS-0077182; D80833
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C23H20Cl2F3N5O2S
|
||||
| IUPAC Name |
1-[1-[3-chloro-4-[2-chloro-4-(trifluoromethoxy)phenoxy]pyridin-2-yl]piperidin-4-yl]-3-pyridin-3-ylthiourea
|
||||
| Canonical SMILES |
C1CN(CCC1NC(=S)NC2=CN=CC=C2)C3=NC=CC(=C3Cl)OC4=C(C=C(C=C4)OC(F)(F)F)Cl
|
||||
| InChI |
InChI=1S/C23H20Cl2F3N5O2S/c24-17-12-16(35-23(26,27)28)3-4-18(17)34-19-5-9-30-21(20(19)25)33-10-6-14(7-11-33)31-22(36)32-15-2-1-8-29-13-15/h1-5,8-9,12-14H,6-7,10-11H2,(H2,31,32,36)
|
||||
| InChIKey |
PIEQDBPBBQPLPL-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Responsed Disease | Fibrosarcoma | ICD-11: 2B53 | ||
| Responsed Regulator | Lysophosphatidylserine lipase ABHD12 | Suppressor | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | HT-1080 cells | Fibrosarcoma | Homo sapiens | CVCL_0317 |
| SU-DHL-5 cells | Diffuse large B-cell lymphoma | Homo sapiens | CVCL_1735 | |
| Response regulation | DO264, a selective inhibitor of the lyso- and ox-phosphatidylserine (PS) lipase ABHD12, enhances ferroptotic death caused by RSL3 in fibrosarcoma cells, an inhibitor of the lipid peroxidase GPX4. | |||